Effects of intranasal oxytocin on symptoms of schizophrenia: A multivariate Bayesian meta-analysis

Psychoneuroendocrinology

Volumn 75, Issue , 2017, Pages 141-151

  Williams, Donald R ^a   Bürkner, Paul Christian ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Intranasal; Meta analysis; Negative symptoms; Oxytocin; Schizophrenia

Indexed keywords

OXYTOCIN; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

CLINICAL EFFECTIVENESS; DATA EXTRACTION; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; BAYES THEOREM;

BAYES THEOREM; HUMANS; NEUROTRANSMITTER AGENTS; OXYTOCIN; SCHIZOPHRENIA;

EID: 84993929557     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2016.10.013     Document Type: Review

References (88)

1. Andreasen, N.C., Nopoulos, P., Schultz, S., Miller, D., Gupta, S., Swayze, V., Flaum, M., Positive and negative symptoms of schizophrenia: past present, and future. Acta Psychiatr. Scand. Suppl. 384 (1994), 51–59.
2. Austin, P.C., Brunner, L.J., Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses. Stat. Med. 23 (2004), 1159–1178, 10.1002/sim.1687.
3. Bürkner, P.-C., 2016. brms: Bayesian Regression Models using Stan.
4. Bales, K.L., Kim, A.J., Lewis-Reese, A.D., Sue Carter, C., Both oxytocin and vasopressin may influence alloparental behavior in male prairie voles. Horm. Behav. 45 (2004), 354–361, 10.1016/j.yhbeh.2004.01.004.
5. Bales, K.L., van Westerhuyzen, J.A., Lewis-Reese, A.D., Grotte, N.D., Lanter, J.A., Carter, C.S., Oxytocin has dose-dependent developmental effects on pair-bonding and alloparental care in female prairie voles. Horm. Behav. 52 (2007), 274–279, 10.1016/j.yhbeh.2007.05.004.
6. Blume, A., Bosch, O.J., Miklos, S., Torner, L., Wales, L., Waldherr, M., Neumann, I.D., Oxytocin reduces anxiety via ERK1/2 activation: local effect within the rat hypothalamic paraventricular nucleus. Eur. J. Neurosci. 27 (2008), 1947–1956, 10.1111/j.1460-9568.2008.06184.x.
7. Buchanan, R.W., Carpenter, W.T., Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J. Nerv. Ment. Dis. 182 (1994), 193–204.
8. Bussolati, G., Cassoni, P., Editorial: The Oxytocin/Oxytocin Receptor System—Expect the Unexpected. 2011, 10.1210/endo.142.4.8147.
9. Buyse, M., Molenberghs, G., Paoletti, X., Oba, K., Alonso, A., der Elst, W., Burzykowski, T., Statistical evaluation of surrogate endpoints with examples from cancer clinical trials. Biom. J. 58:1 (2016), 104–132.
10. Cacciotti-Saija, C., Langdon, R., Ward, P.B., Hickie, I.B., Scott, E.M., Naismith, S.L., Moore, L., Alvares, G.A., Redoblado Hodge, M.A., Guastella, A.J., A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis. Schizophr. Bull. 41 (2015), 483–493, 10.1093/schbul/sbu094.
11. Carpenter, B., Gelman, A., Hoffman, M., Lee, D., Goodrich, B., Betancour, M., Brubaker, M.A., Guo, J., Li, P., Ridell, A., \pkg{Stan}: a probabilistic programming language. J. Stat. Softw., 2015.
12. Cho, M.M., DeVries, a C., Williams, J.R., Carter, C.S., The effects of oxytocin and vasopressin on partner preferences in male and female prairie voles (Microtus ochrogaster). Behav. Neurosci. 113 (1999), 1071–1079, 10.1037/0735-7044.113.5.1071.
13. Cushing, B.S., Carter, C.S., Peripheral pulses of oxytocin increase partner preferences in female, but not male, prairie voles. Horm. Behav. 37 (2000), 49–56, 10.1006/hbeh.1999.1558.
14. Dagani, J., Sisti, D., Abelli, M., Di Paolo, L., Pini, S., Raimondi, S., Rocchi, M.B., Saviotti, F.M., Scocco, P., Totaro, S., Balestrieri, M., de Girolamo, G., Do we need oxytocin to treat schizophrenia? A randomized clinical trial. Schizophr. Res. 172 (2016), 158–164, 10.1016/j.schres.2016.02.011.
15. Davis, M.C., Green, M.F., Lee, J., Horan, W.P., Senturk, D., Clarke, A.D., Marder, S.R., Oxytocin-augmented social cognitive skills training in schizophrenia. Neuropsychopharmacology 39 (2014), 2070–2077, 10.1038/npp.2014.68.
16. Deeks, J.J., Higgins, J.P.T., Altman, D.G., Chapter 9: analysing data and undertaking meta-analyses. Cochrane Handb. Syst. Rev. Interv. Version, 2008, 243–296.
17. Domes, G., Heinrichs, M., Michel, A., Berger, C., Herpertz, S.C., Oxytocin improves mind-reading in humans. Biol. Psychiatry, 2007, 10.1016/j.biopsych.2006.07.015.
18. Domes, G., Lischke, A., Berger, C., Grossmann, A., Hauenstein, K., Heinrichs, M., Herpertz, S.C., Effects of intranasal oxytocin on emotional face processing in women. Psychoneuroendocrinology 35 (2010), 83–93, 10.1016/j.psyneuen.2009.06.016.
19. Duval, S., Tweedie, R., Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56 (2000), 455–463.
20. Ellenbroek, B.A., Psychopharmacological treatment of schizophrenia: what do we have, and what could we get?. Neuropharmacology 62 (2012), 1371–1380, 10.1016/j.neuropharm.2011.03.013.
21. Ellenbroek, B.A., Psychopharmacological treatment of schizophrenia: what do we have, and what could we get?. Neuropharmacology 62 (2012), 1371–1380, 10.1016/j.neuropharm.2011.03.013.
22. Feifel, D., Shilling, P.D., MacDonald, K., A review of oxytocin's effects on the positive, negative, and cognitive domains of schizophrenia. Biol. Psychiatry 79 (2016), 222–233, 10.1016/j.biopsych.2015.07.025.
23. Freeman, S.M., Samineni, S., Allen, P.C., Stockinger, D., Bales, K.L., Hwa, G.G.C., Roberts, J.A., Plasma and CSF oxytocin levels after intranasal and intravenous oxytocin in awake macaques. Psychoneuroendocrinology 66 (2016), 185–194, 10.1016/j.psyneuen.2016.01.014.
24. Gelman, A., Prior distributions for variance parameters in hierarchical models. Bayesian Anal. 1 (2006), 515–534.
25. Gibson, C.M., Penn, D.L., Smedley, K.L., Leserman, J., Elliott, T., Pedersen, C.A., A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia. Schizophr. Res. 156 (2014), 261–265, 10.1016/j.schres.2014.04.009.
26. Gibson, C.M., Penn, D.L., Smedley, K.L., Leserman, J., Elliott, T., Pedersen, C.A., A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia. Schizophr. Res. 156 (2014), 261–265, 10.1016/j.schres.2014.04.009.
27. Guastella, A.J., Einfeld, S.L., Gray, K.M., Rinehart, N.J., Tonge, B.J., Lambert, T.J., Hickie, I.B., Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol. Psychiatry, 2010, 10.1016/j.biopsych.2009.09.020.
28. Gumley, A., Braehler, C., Macbeth, A., A meta-analysis and theoretical critique of oxytocin and psychosis: prospects for attachment and compassion in promoting recovery. Br. J. Clin. Psychol. 53 (2014), 42–61, 10.1111/bjc.12041.
29. Higgins, J.P.T., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat. Med. 21 (2002), 1539–1558.
30. Ho, B.C., Nopoulos, P., Flaum, M., Arndt, S., Andreasen, N.C., Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am. J. Psychiatry 155 (1998), 1196–1201, 10.1176/ajp.155.9.1196.
31. Hofmann, S.G., Fang, A., Brager, D.N., Effect of intranasal oxytocin administration on psychiatric symptoms: a meta-analysis of placebo-controlled studies. Psychiatry Res. 228 (2015), 708–714, 10.1016/j.psychres.2015.05.039.
32. Hofmann, S.G., Fang, A., Brager, D.N., Effect of intranasal oxytocin administration on psychiatric symptoms: a meta-analysis of placebo-controlled studies. Psychiatry Res. 228 (2015), 708–714, 10.1016/j.psychres.2015.05.039.
33. Huedo-Medina, T.B., Sánchez-Meca, J., Marín-Martínez, F., Botella, J., Assessing heterogeneity in meta-analysis: Q statistic or I$^2$ index?. Psychol. Methods, 11, 2006, 193.
34. Jeffreys, H., The Theory of Probability. 1998, Oxford University Press, Oxford.
35. Kay, S.R., Flszbein, A., Opfer, L.A., The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull., 13, 1987, 261.
36. Kendler, K.S., Neale, M.C., Walsh, D., Evaluating the spectrum concept of schizophrenia in the roscommon family study. Am. J. Psychiatry, 152(5), 1995, 749.
37. Khandaker, G.M., Zimbron, J., Lewis, G., Jones, P.B., Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol. Med. 43 (2013), 239–257, 10.1017/S0033291712000736.
38. Kingwell, K., Schizophrenia drug gets negative results for negative symptoms. Nat. Rev. Drug Discov. 13 (2014), 244–245, 10.1038/nrd4294.
39. Kirkpatrick, B., Fenton, W.S., Carpenter, W.T., Marder, S.R., The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 32 (2006), 214–219, 10.1093/schbul/sbj053.
40. Kuroki, T., Nagao, N., Nakahara, T., Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin–dopamine hypothesis. Prog. Brain Res. 172 (2008), 199–212, 10.1016/S0079-6123(08)00910-2.
41. Lançon, C., Auquier, P., Nayt, G., Reine, G., Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophr. Res. 42 (2000), 231–239, 10.1016/S0920-9964(99)00129-2.
42. Lane, A., Luminet, O., Nave, G., Mikolajczak, M., Is there a publication bias in behavioural intranasal oxytocin research on humans? opening the file drawer of one laboratory. J. Neuroendocrinol., 28, 2016, 10.1111/jne.12384.
43. Lawrie, S.M., Abukmeil, S.S., Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br. J. Psychiatry 172 (1998), 110–120, 10.1192/bjp.172.2.110.
44. Lee, M.R., Wehring, H.J., McMahon, R.P., Linthicum, J., Cascella, N., Liu, F., Bellack, A., Buchanan, R.W., Strauss, G.P., Contoreggi, C., Kelly, D.L., Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study. Schizophr. Res. 145 (2013), 110–115, 10.1016/j.schres.2013.01.001.
45. Leng, G., Ludwig, M., Intranasal oxytocin: myths and delusions. Biol. Psychiatry 79 (2016), 243–250, 10.1016/j.biopsych.2015.05.003.
46. Leucht, S., Corves, C., Arbter, D., Engel, R.R., Li, C., Davis, J.M., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373 (2009), 31–41, 10.1016/S0140-6736(08)61764-X.
47. Lischke, A., Berger, C., Prehn, K., Heinrichs, M., Herpertz, S.C., Domes, G., Intranasal oxytocin enhances emotion recognition from dynamic facial expressions and leaves eye-gaze unaffected. Psychoneuroendocrinology 37 (2012), 475–481, 10.1016/j.psyneuen.2011.07.015.
48. Liu, Y., Wang, Z., Nucleus accumbens oxytocin and dopamine interact to regulate pair bond formation in female prairie voles. Neuroscience 121:3 (2003), 537–544.
49. Love, T.M., Oxytocin, motivation and the role of dopamine. Pharmacol. Biochem. Behav. 119 (2014), 49–60, 10.1016/j.pbb.2013.06.011.
50. Merritt, K., McGuire, P., Egerton, A., Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis. Front. Psychiatry 4 (2013), 1–8, 10.3389/fpsyt.2013.00151.
51. Millan, M.J., Fone, K., Steckler, T., Horan, W.P., Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur. Neuropsychopharmacol. 24 (2014), 645–692, 10.1016/j.euroneuro.2014.03.008.
52. Modabbernia, A., Rezaei, F., Salehi, B., Jafarinia, M., Ashrafi, M., Tabrizi, M., Hosseini, S.M.R., Tajdini, M., Ghaleiha, A., Akhondzadeh, S., Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs 27 (2013), 57–65, 10.1007/s40263-012-0022-1.
53. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int. J. Surg. 8 (2010), 336–341, 10.1016/j.ijsu.2010.02.007.
54. Montag, C., Brockmann, E.-M., Bayerl, M., Rujescu, D., Müller, D.J., Gallinat, J., Oxytocin and oxytocin receptor gene polymorphisms and risk for schizophrenia: a case-control study. World J. Biol. Psychiatry, 14(7), 2013, 10.3109/15622975.2012.677547.
55. Morris, S.B., DeShon, R.P., Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. Psychol. Methods, 7, 2002, 105, 10.1037/1082-989X.7.1.105.
56. Nave, G., Camerer, C., McCullough, M., Does oxytocin increase trust in humans? a critical review of research. Perspect. Psychol. Sci. 10 (2015), 772–789, 10.1177/1745691615600138.
57. O'Donovan, M.C., Craddock, N., Norton, N., Williams, H., Peirce, T., Moskvina, V., Nikolov, I., Hamshere, M., Carroll, L., Georgieva, L., Dwyer, S., Holmans, P., Marchini, J.L., Spencer, C.C.A., Howie, B., Leung, H.-T., Hartmann, A.M., Möller, H.-J., Morris, D.W., Shi, Y., Feng, G., Hoffmann, P., Propping, P., Vasilescu, C., Maier, W., Rietschel, M., Zammit, S., Schumacher, J., Quinn, E.M., Schulze, T.G., Williams, N.M., Giegling, I., Iwata, N., Ikeda, M., Darvasi, A., Shifman, S., He, L., Duan, J., Sanders, A.R., Levinson, D.F., Gejman, P., Gejman, V., V, P., Sanders, A.R., Duan, J., Levinson, D.F., Buccola, N.G., Mowry, B.J., Freedman, R., Amin, F., Black, D.W., Silverman, J.M., Byerley, W.F., Cloninger, C.R., Cichon, S., Nöthen, M.M., Gill, M., Corvin, A., Rujescu, D., Kirov, G., Owen, M.J., Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat. Genet. 40 (2008), 1053–1055, 10.1038/ng.201.
58. Oya, K., Matsuda, Y., Matsunaga, S., Kishi, T., Iwata, N., Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials. Eur. Arch. Psychiatry Clin. Neurosci., 2015, 10.1007/s00406-015-0634-9.
59. Packer, S., Husted, J., Cohen, S., Tomlinson, G., Psychopathology and quality of life in schizophrenia. J. Psychiatry Neurosci. 22 (1997), 231–234.
60. Padmanabhan, J.L., Tandon, N., Haller, C.S., Mathew, I.T., Eack, S.M., Clementz, B.A., Pearlson, G.D., Sweeney, J.A., Tamminga, C.A., Keshavan, M.S., Correlations between brain structure and symptom dimensions of psychosis in schizophrenia, schizoaffective, and psychotic bipolar i disorders. Schizophr. Bull. 41 (2015), 154–162, 10.1093/schbul/sbu075.
61. Pedersen, C.A., Gibson, C.M., Rau, S.W., Salimi, K., Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophrenia 132:1 (2011), 50–53.
62. Pedersen, C.A., Gibson, C.M., Rau, S.W., Salimi, K., Smedley, K.L., Casey, R.L., Leserman, J., Jarskog, L.F., Penn, D.L., Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr. Res. 132 (2011), 50–53, 10.1016/j.schres.2011.07.027.
63. Peralta, V., Cuesta, M.J., Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Res. 53 (1994), 31–40, 10.1016/0165-1781(94)90093-0.
64. Peralta, V., Cuesta, M.J., Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Res. 53 (1994), 31–40, 10.1016/0165-1781(94)90093-0.
65. Qeoffrey Davies, Welham, J., Chant, D., Fuller Torrey, E., McQrath, J., A systematic review and meta-analysis of northern Hemisphere season of birth studies in schizophrenia. Schizophr. Bull., 29(3), 2003, 587.
66. Quintana, D.S., Woolley, J.D., Intranasal oxytocin mechanisms can be better understood, but its effects on social cognition and behavior are not to be sniffed at. Biol. Psychiatry, 2016, 10.1016/j.biopsych.2015.06.021.
67. R Core Development Team, R: A Language and Environment for Statistical Computing, 3.2.1. Doc. 2016, 10.1017/CBO9781107415324.004 Free. available internet http//www.r-project.org.
68. Rabinowitz, J., Levine, S.Z., Garibaldi, G., Bugarski-Kirola, D., Berardo, C.G., Kapur, S., Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr. Res. 137 (2012), 147–150, 10.1016/j.schres.2012.01.015.
69. Royston, P., Altman, D.G., Sauerbrei, W., Dichotomizing continuous predictors in multiple regression: a bad idea. Stat. Med. 25 (2006), 127–141, 10.1002/sim.2331.
70. Rubin, L.H., Carter, C.S., Drogos, L., Pournajafi-Nazarloo, H., Sweeney, J.A., Maki, P.M., Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr. Res. 124 (2010), 13–21, 10.1016/j.schres.2010.09.014.
71. Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Kissling, W., Davis, J.M., Leucht, S., Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr. Bull. 38 (2012), 167–177, 10.1093/schbul/sbq042.
72. Saha, S., Chant, D., Welham, J., McGrath, J., A systematic review of the prevalence of schizophrenia. PLoS Med. 2 (2005), 0413–0433, 10.1371/journal.pmed.0020141.
73. Shahrestani, S., Kemp, A.H., Guastella, A.J., The impact of a single administration of intranasal oxytocin on the recognition of basic emotions in humans: a meta-analysis. Neuropsychopharmacology 38 (2013), 1929–1936, 10.1038/npp.2013.86.
74. Sterne, J.A.C., Egger, M., Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J. Clin. Epidemiol. 54 (2001), 1046–1055.
75. Sterne, J.A.C., Sutton, A.J., Ioannidis, J.P.A., Terrin, N., Jones, D.R., Lau, J., Carpenter, J., Cker, G., Harbord, R.M., Schmid, C.H., Tetzlaff, J., Deeks, J.J., Peters, J., MacAskill, P., Schwarzer, G., Duval, S., Altman, D.G., Moher, D., Higgins, J.P.T., Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343 (2011), 1–8.
76. Striepens, N., Kendrick, K.M., Maier, W., Hurlemann, R., Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. Front. Neuroendocrinol. 32 (2011), 426–450, 10.1016/j.yfrne.2011.07.001.
77. Sullivan, P.F., Kendler, K.S., Neale, M.C., Schizophrenia as a complex trait. Arch. Gen. Psychiatry 60 (2003), 1187–1192, 10.1001/archpsyc.60.12.1187.
78. Thompson, S.G., Higgins, J.P.T., How should meta-regression analyses be undertaken and interpreted?. Stat. Med. 21 (2002), 1559–1573, 10.1002/sim.1187.
79. Thornton, A., Lee, P., Publication bias in meta-analysis: its causes and consequences. J. Clin. Epidemiol. 53 (2000), 207–216, 10.1016/S0895-4356(99)00161-4.
80. Tomizawa, K., Iga, N., Lu, Y.-F., Moriwaki, A., Matsushita, M., Li, S.-T., Miyamoto, O., Itano, T., Matsui, H., Oxytocin improves long-lasting spatial memory during motherhood through MAP kinase cascade. Nat. Neurosci. 6 (2003), 384–390, 10.1038/nn1023.
81. Van IJzendoorn, M.H., Bakermans-Kranenburg, M.J., A sniff of trust: meta-analysis of the effects of intranasal oxytocin administration on face recognition, trust to in-group, and trust to out-group. Psychoneuroendocrinology, 2012, 10.1016/j.psyneuen.2011.07.008.
82. Viechtbauer, W., Conducting meta-analyses in R with the metafor package. J. Stat. Softw. 36 (2010), 1–48.
83. Viero, C., Shibuya, I., Kitamura, N., Verkhratsky, A., Fujihara, H., Katoh, A., Ueta, Y., Zingg, H.H., Chvatal, A., Sykova, E., Dayanithi, G., Oxytocin: crossing the bridge between basic science and pharmacotherapy. CNS Neurosci. Ther. 16 (2010), 138–156, 10.1111/j.1755-5949.2010.00185.x.
84. Wagenmakers, E.-J., Lodewyckx, T., Kuriyal, H., Grasman, R., Bayesian hypothesis testing for psychologists: a tutorial on the Savage-Dickey method. Cogn. Psychol. 60 (2010), 158–189, 10.1016/j.cogpsych.2009.12.001.
85. Walum, H., Waldman, I.D., Young, L.J., Statistical and methodological considerations for the interpretation of intranasal oxytocin studies. Biol. Psychiatry 79 (2016), 251–257, 10.1016/j.biopsych.2015.06.016.
86. Williams, D.R., Burkner, P.-C., 2016. Coding errors lead to unsupported conclusions: a critique of Hofmann et al. (2015).
87. Williams, D.R., Burkner, P.-C., 2016. Data extraction and statistical errors: a quantitative critique of Gumley, Braehler, & Macbeth (2014).
88. Winton-Brown, T.T., Fusar-Poli, P., Ungless, M.A., Howes, O.D., Dopaminergic basis of salience dysregulation in psychosis. Trends Neurosci. 37 (2014), 85–94, 10.1016/j.tins.2013.11.003.